Research location
Paderborn
Germany
Advertisement
Research activity in Paderborn
GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 61 trials and 67 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Paderborn
61 linked trials · page 1 of 2A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast CancerNCT07563595 · 2026-06-19 · 1 site observation
RECRUITING
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerNCT07647328 · 2026-06-15 · 1 site observation
RECRUITING
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveNCT07413939 · 2026-05-21 · 1 site observation
RECRUITING
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerNCT07054190 · 2025-09-09 · 1 site observation
RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation
RECRUITING
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07 · 1 site observation
RECRUITING
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerNCT05306041 · 2023-01-02 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation
RECRUITING
BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection FractionNCT02880618 · 2016-12-13 · 1 site observation
RECRUITING
AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial FibrillationNCT07604727 · 2026-07-01 · 1 site observation
NOT_YET_RECRUITING
Reoperation Rate in Breast-Conserving Surgery Using Confocal Histolog® Scanner for Intraoperative Margin AssessmentNCT05946759 · 2023-10-10 · 1 site observation
COMPLETED
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryNCT05549505 · 2023-02-15 · 1 site observation
COMPLETED
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585 · 2022-11-28 · 1 site observation
ACTIVE_NOT_RECRUITING
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal TherapiesNCT05043506 · 2022-02-08 · 1 site observation
COMPLETED
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerNCT05113251 · 2021-10-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934 · 2021-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)NCT04784715 · 2021-04-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NCT04623775 · 2021-02-17 · 1 site observation
COMPLETED
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · 2020-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)NCT04576455 · 2020-11-27 · 1 site observation
ACTIVE_NOT_RECRUITING
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.NCT04767594 · 2020-10-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Assessment of Lumpectomy Margins With the Histolog Scanner in Comparison With Intraoperative Imaging TechniquesNCT05118568 · 2020-10-01 · 1 site observation
COMPLETED
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyNCT04471428 · 2020-10-01 · 1 site observation
COMPLETED
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerNCT04305496 · 2020-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-EtoposideNCT04221529 · 2020-01-06 · 1 site observation
COMPLETED
A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerNCT03988114 · 2019-09-16 · 1 site observation
WITHDRAWN
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerNCT03726879 · 2019-01-11 · 1 site observation
COMPLETED
Re-evaluation of Optimal Re-synchronisation Therapy in Patients With Chronic Heart FailureNCT03494933 · 2018-09-01 · 1 site observation
TERMINATED
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerNCT03417037 · 2018-05-24 · 1 site observation
WITHDRAWN
REDUCE LAP-HF III Corvia Protocol 1701NCT03191656 · 2017-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)NCT02409355 · 2015-05-07 · 1 site observation
TERMINATED
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.NCT02296138 · 2015-01-13 · 1 site observation
COMPLETED
Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill ParentsNCT02308462 · 2014-11-01 · 1 site observation
COMPLETED
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerNCT02032823 · 2014-04-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid ArthritisNCT02000336 · 2014-01-01 · 1 site observation
COMPLETED
Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPDNCT01892488 · 2013-06-07 · 1 site observation
COMPLETED
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)NCT01772472 · 2013-04-03 · 1 site observation
COMPLETED
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)NCT01585298 · 2012-04-29 · 1 site observation
COMPLETED
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)NCT01285167 · 2010-08-01 · 1 site observation
COMPLETED
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPDNCT01285180 · 2010-08-01 · 4 site observations
COMPLETED
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseaseNCT01126437 · 2010-05-01 · 1 site observation
COMPLETED
Observation of Treatment With Certolizumab Pegol in Daily PracticeNCT01069419 · 2009-10-01 · 1 site observation
COMPLETED
Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or mNCT00997230 · 2009-09-01 · 1 site observation
COMPLETED
Effectiveness and Safety of Firmagon®NCT00930319 · 2009-06-01 · 1 site observation
COMPLETED
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart FailureNCT00894387 · 2009-05-01 · 1 site observation
COMPLETED
Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's DiseaseNCT00752388 · 2008-11-01 · 1 site observation
COMPLETED
Survival of Patients With Primary Prophylactic ICD IndicationNCT00619593 · 2008-02-01 · 1 site observation
COMPLETED
Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AFNCT00643188 · 2008-01-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.